announcement stirlingpharma gains site license

Official Announcement:

Stirling Pharma Gains Health
Canada Site Licence
15 October 2010
Healthcare group, Stirling Products Limited (ASX:STI) advises that Stirling Pharma Inc, the Company's wholly owned Canadian subsidiary, has been issued a Site License issued by Health Canada's Minister of Health under the authority of the Natural Health Products Regulations for the manufacturing, packaging and labelling of natural health products at its manufacturing facility located in North Sydney, Nova Scotia.
The issuance of this license permits the Company's Cape Breton, Nova Scotia facility to manufacture supplements and natural health products. The Company further advises that Health Canada has advised that an inspection for the issue
of an Establishment License has been scheduled over a number of days commencing 29 November 2010. Following this inspection a full Establishment License is expected to issue
that will then allow Stirling Pharma to manufacture pharmaceutical drugs.
The Company's 46,000 sq. ft. Cape Breton high-tech GMP pharmaceutical plant includes laboratories for formulation development and includes specialist sections having various
capabilities such as high shear mixing, container blending and equipment for the manufacture of modified drug release product. The facility provides formulation development and testing services, as well as provision for the manufacture and packaging of products in solid and liquid dosage forms. With current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product.

For further information see www.stirlingproducts.net or contact:
Peter Boonen - Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E: [email protected]
For all Investor Relations inquiries please contact:
James Moses - Mandate Corporate
Ph: +61 420 991 574
E: [email protected]